Literature DB >> 1803996

Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

H Sun1, M S Chow, E G Maderazo.   

Abstract

The interaction between immunoglobulin G (IgG) and ceftriaxone was studied. Using an ultrafiltration method, we performed dose ranging studies at a ceftriaxone concentration range of 1 to 720 micrograms/ml in the presence of various concentrations of human IgG, human serum albumin (HSA), and combinations of IgG and HSA at pH 7.4 and 37 degrees C. The results showed that ceftriaxone binding to IgG was nonlinear and was consistent with the presence of two binding sites that possess different binding capacities and affinities. Except for increased peak percent binding as the IgG concentration increased, the binding characteristics did not change with IgG concentration. Binding to HSA was consistent, with the presence of only one high-affinity binding site. A mathematical model based on the observed data was constructed; this model was used to predict protein binding at various concentrations of drug, IgG, HSA, or combinations of IgG and HSA in buffer and in plasma medium. Correlations between the observed versus the predicted values were excellent in both media. Simulations with the model indicated that patients with hypergammaglobulinemia have an increased potential of being exposed to prolonged subinhibitory concentrations of ceftriaxone if the drug is given once every 24 h.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1803996      PMCID: PMC245365          DOI: 10.1128/AAC.35.11.2232

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Estimation of drug binding parameters.

Authors:  R H Luecke; W D Wosilait
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

3.  Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.

Authors:  D J Winston; W G Ho; C H Lin; K Bartoni; M D Budinger; R P Gale; R E Champlin
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

Review 4.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

5.  Single-dose ceftriaxone kinetics in liver insufficiency.

Authors:  K Stoeckel; H Tuerk; V Trueb; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

6.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  High-dose intravenous immune globulin impairs antibacterial activity of antibiotics.

Authors:  K S Kim
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793

8.  Factors affecting ceftriaxone plasma protein binding during open heart surgery.

Authors:  G L Jungbluth; M T Pasko; W J Jusko
Journal:  J Pharm Sci       Date:  1989-10       Impact factor: 3.534

9.  Single-dose ceftriaxone kinetics in the newborn.

Authors:  U B Schaad; W L Hayton; K Stoeckel
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  2 in total

1.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

2.  Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.

Authors:  Matthias Gijsen; Erwin Dreesen; Ruth Van Daele; Pieter Annaert; Yves Debaveye; Joost Wauters; Isabel Spriet
Journal:  Antibiotics (Basel)       Date:  2021-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.